Clinical Trial VICCURO1187
A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
- Protocol No. VICCURO1187
- Open Date: 02/14/2012
- Staging: Phase II
- Age Group: Adults
- Scope: National
- Objective: To evaluate overall survival following administration of DN24-02.
- Disease Sites: Urologic
- Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
- Drugs: DN24-02
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: N10-1
Not provided. Please call for more information.